Advertisement
Advertisement
U.S. Markets open in 2 hrs 30 mins
Advertisement
Advertisement
Advertisement
Advertisement

Amneal Pharmaceuticals, Inc. (AMRX)

NYSE - NYSE Delayed Price. Currency in USD
1.5300+0.1000 (+6.99%)
At close: 04:00PM EDT
1.5400 +0.01 (+0.65%)
After hours: 07:50PM EDT
Advertisement

Amneal Pharmaceuticals, Inc.

400 Crossing Boulevard
3rd Floor
Bridgewater, NJ 08807
United States
908 947 3120
https://www.amneal.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees7,000

Key Executives

NameTitlePayExercisedYear Born
Mr. Chirag K. PatelCo-Founder, Co-CEO, Pres & Director1.52MN/A1967
Mr. Chintu Patel R.Ph, R.Ph.Co-Founder, Co-CEO & Director1.53MN/A1972
Mr. Anastasios G. KonidarisExec. VP & CFO893.24kN/A1967
Ms. Nikita ShahExec. VP & Chief HR Officer807.09k149.58k1979
Mr. Andrew S. BoyerExec. VP & Chief Commercial Officer of Generics1.1MN/A1966
Mr. Anthony DiMeoSr. Director of Investor RelationsN/AN/AN/A
Mr. Jason B. Daly Esq.Sr. VP, Chief Legal Officer & Corp. Sec.N/AN/A1974
Mr. Sanjiv PatelSr. VP of OperationsN/AN/AN/A
Dr. Nikunj PatelHead of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt LtdN/AN/AN/A
Mr. Sanjay Kumar Jain Ph.D.Pres of India OperationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Corporate Governance

Amneal Pharmaceuticals, Inc.’s ISS Governance QualityScore as of February 1, 2023 is 5. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 4; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement